Top

Administration and Policy in Mental Health and Mental Health Services Research

Published in:

01-03-2006

An Economic Comparison of Risperidone and Olanzapine Use within an Integrated Managed Mental Health Program

Authors: Michael Johnsrud, M. Lynn. Crismon, Ann Thompson, Amy Grogg

Published in: Administration and Policy in Mental Health and Mental Health Services Research | Issue 2/2006

This study assessed differences in total mental health care costs for 1 year following initiation of risperidone or olanzapine in individuals within NorthSTAR, an integrated managed mental health pilot project. A retrospective database analysis of individuals with schizophrenia or schizoaffective disorder and newly started on either agent was conducted. Antipsychotic medication costs were significantly lower for individuals prescribed risperidone than olanzapine ($1763 versus $2582; p<0.001). Individuals prescribed risperidone had lower (but not significant) expenditures for mental health services ($4714 versus $5077; p=0.792), as well as total mental health care costs ($7407 versus $9011; p=0.255).

American Psychiatric Association. Practice. (2004). Guideline for the treatment of patients with schizophrenia: second edition. February 2004. Arlington, VA

Baker J (2001) Engaging the community mental health stakeholders in pharmacy cost management. Psychiatric Services 52:650–3PubMedCrossRef

Bhana N, Foster RH, Olney R, et al (2001) Olanzapine: An update review of its use in the management of schizophrenia. Drugs 61:111–61PubMedCrossRef

Buck J (2001) Managed mental health care in Medicaid: Does the solution match the problem? Administration and Policy in Mental Health 29:177–80PubMedCrossRef

Crown WH, Neslusan C, Russo PA, et al. (2001) Hospitalization and total medical costs for privately insured persons with schizophrenia. Administration and Policy in Mental Health 28:335–51PubMedCrossRef

Fuller MA, Shermock KM, Secic M, et al (2002) Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatric Services 53:855–60PubMedCrossRef

Kasper S, Jones M, Duchesne I (2001) Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. International Clinical Psychopharmacology 16:189–96PubMedCrossRef

Kelly DL, Nelson MW, Love RC, et al (2001) Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatric Services 52:676–8PubMedCrossRef

Lewis M, McCrone P, Frangou S (2001) Service use and costs of treating schizophrenia with atypical antipsychotics. Journal of Clinical Psychiatry 62:749–56PubMed

Liu GG, Sun SX, Christensen DB, et al. (2004) Cost comparisons of olanzapine and risperidone in treating schizophrenia. Annals of Pharmacotherapy 38: 134–141PubMedCrossRef

McFarland BH, Khorramzadeh S, Millins R, et al (2002) Psychiatric hospital length of stay for Medicaid clients before and after managed care. Administration and Policy in Mental Health 29:191–9PubMedCrossRef

Miller AL, Hall CS, Buchanan RW, et al (2004) The Texas Medication Algorithm Project: antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry 65 (4): 500–8PubMedCrossRef

Prochshyn RM, Zerjav S (1998) Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clinical Therapeutics 20:1203–17CrossRef

Rabinowitz J, Lichtenberg P, Kaplan Z (2000) Comparison of cost, dosage and clinical preference for risperidone and olanzapine.Schizophrenia Research 46:91–6PubMedCrossRef

Sturm R, Jackson CA, Meredith LS, et al (1995) Mental health care utilization in prepaid and fee-for-service plans among depressed patients in the Medical Outcomes Study. Health Services Research 30:319–40PubMed

Texas Health and Human Services Commission. (1999). Press Release, September 14, Austin, TX.

Zhao Z (2002) A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Managed Care Interface 15:75–81PubMed

Title: An Economic Comparison of Risperidone and Olanzapine Use within an Integrated Managed Mental Health Program
Authors: Michael Johnsrud
M. Lynn. Crismon
Ann Thompson
Amy Grogg
Publication date: 01-03-2006
Publisher: Springer US
Published in: Administration and Policy in Mental Health and Mental Health Services Research / Issue 2/2006
Print ISSN: 0894-587X
Electronic ISSN: 1573-3289
DOI: https://doi.org/10.1007/s10488-005-0018-y

At a glance: The STEP trials

Springer Medicine

An Economic Comparison of Risperidone and Olanzapine Use within an Integrated Managed Mental Health Program

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2006

Poor and Depressed, The Tip of the Iceberg: The Unmet Needs of Enrollees in an Indigent Health Care Plan

Adolescent Primary Care Patients’ Preferences for Depression Treatment

School-Based Mental Health Services for Children Living in High Poverty Urban Communities

Management of Mental Disorders in VA Primary Care Practices

Use of the Family Resource Scale in Children’s Mental Health: Reliability and Validity among Economically Diverse Samples

Mental Health Care Deficiency Citations in Nursing Homes and Caregiver Staffing